Kenvue shares (KVUE) are in focus Monday after the consumer health firm ousted its CEO, Thibaut Mongon, and announced a strategic review aimed at optimizing the portfolio.
Kirk Perry will be the interim chief executive as the company searches for a permanent replacement, it confirmed in a press release on July 14.
At the time of writing, Kenvue stock is down more than 13% versus its year-to-date high in May.
Kenvue’s leadership shake-up and strategic review could prove meaningfully positive for its stock price as they signal a proactive reset aimed at unlocking shareholder value.
The company based out of Summit, New Jersey appointed Kirk Perry, a seasoned executive with deep experience in consumer goods and data-driven transformation, indicating utter commitment to operational discipline.
Plus, the board’s review could lead to brand divestitures, cost savings, and portfolio simplification, all of which may improve margins and focus over time.
Simply put, the management change and strategic review announced today positions KVUE shares for stronger execution and long-term growth.
Kenvue shares are currently trading only slightly above the price at which they started this year, weakness that Jefferies analysts dubbed an opportunity to buy a quality name at a deep discount in their latest research note.
In June, the investment firm called KVUE a “self-help transformation story” as it reiterated its “Buy” rating on the consumer health firm.
According to Jefferies, improving retail trends and early recovery in key brands like Neutrogena and Zyrtec could see KVUE stock hitting $27 (up more than 27% from here) over the next 12 months.
A rather lucrative 3.74% dividend yield makes up for another great reason to own Kenvue in the second half of 2025.
While not as bullish as Jefferies, other Wall Street firms also recommend buying KVUE shares at current levels.
According to Barchart, the consensus rating on Kenvue stock currently sits at “Moderate Buy” with the mean target of $24.50 indicating potential upside of more than 12% from here.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
